NeoStem and PCT, A NeoStem Company, to Present at Multiple September Conferences

NEW YORK, Sept. 9, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), will present at multiple upcoming conferences in September.

Rodman & Renshaw 16th Annual Global Investment Conference

  • Date and Time: Tuesday, September 9, 2014, 10:25 AM EDT
  • Venue: New York Palace Hotel, New York, New York
  • Speaker: Dr. Robin Smith, Chairman, Chief Executive Officer, NeoStem
  • Topic: Company Presentation
  • Site:

Aegis Capital Healthcare and Technology Conference

  • Date and Time: Thursday, September 11, 2014, 11:25 AM PDT
  • Venue: The Encore at Wynn Las Vegas, Las Vegas, Nevada
  • Speaker: Dr. Robin Smith, Chairman, Chief Executive Officer, NeoStem
  • Topic: Company Presentation
  • Website:

IBC's 4th Annual Cell Therapy Processing

  • Date and Time: Monday, September 15, 2014, 5:00 PM EDT
  • Venue: Sheraton Pentagon City, Arlington, VA
  • Speaker: Dr. Ian Gaudet, Senior Engineer, PCT
  • Topic: New Cell Washing Concept Utilizing Spinning Membrane Device
  • Website:

Stem Cells and Regenerative Medicine Congress 2014

Session 1

  • Date and Time: Monday, September 15, 2014, 4:00 PM EDT
  • Speaker: Dr. Adel Nada, Vice President, Immunotherapy
  • Topic: Regulatory T Cell Therapy for Type 1 Diabetes, Can a single treatment change the natural history of chronic disease?

Session 2

  • Date and Time: Tuesday, September 16, 2014, 12:20 PM EDT
  • Speaker: Dr. Cenk Sumen, Manager of Technology & Business Development, PCT
  • Topic: Streamlining the path to commercial success for cell therapy

International Society for Cellular Therapy Webinar

  • Date: Wednesday, September 24, 2014, 12:00 PM EDT
  • Speakers: Brian Hampson, Vice President, Engineering & Innovation, PCT, and Robert Shaw, Vice President, Commercial Development, PCT
  • Topic: Building Deliverable Cell Therapeutics: A Methodical Approach to Manufacturing Development
  • Website:

NewsMakers in the Biotech Industry

About NeoStem, Inc.

NeoStem is a leader in the emerging cellular therapy industry, pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, the Company's ability to develop and grow its business, the successful development of cellular therapies with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's Targeted Cancer Immunotherapy Program, Ischemic Repair Program, Immune Modulation Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the performance and planned expansion of the Company's contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 13, 2014, the Company's Current Report on Form 8-K filed with the SEC on May 8, 2014 and in the Company's other periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: Investor Contact: LifeSci Advisors, LLC Michael Rice Founding Partner Phone: +1-646-597-6979 Email: Media Contact: NeoStem, Inc. Eric Powers Manager of Communications and Marketing Phone: +1-212-584-4173 Email:

Source:NeoStem Inc.